ArticleThe South African journal of physiotherapy2026
Cystic fibrosis transmembrane conductance regulator modulator therapy and lived experiences in South Africa: A mixed-methods study.
Article in The South African journal of physiotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cystic fibrosis transmembrane conductance regulator modulator (CFTRm) therapy has transformed cystic fibrosis (CF) outcomes in high-income settings, yet access remains severely limited in South Africa. Patient-reported outcomes of CFTRm are underexplored. Objectives: To describe the lived experiences of South African people living with cystic fibrosis (PLwCF) following CFTRm initiation, focusing on respiratory symptoms, treatment burden, physical activity, social and recreational participation, and well-being. Method: A convergent mixed-methods design incorporated an online survey ( Results: Participants reported dramatic improvements from pre- to post-CFTRm: daily distressing respiratory symptoms decreased from 73% to 6% ( Conclusion: Cystic fibrosis transmembrane conductance regulator modulator profoundly transforms the lived experiences of South African PLwCF providing compelling evidence to advocate for equitable access in resource-limited settings. Clinical Implications: National funding and rollout of CFTRm for all eligible PLwCF in South Africa are urgently needed, together with interdisciplinary support to navigate modifications to existing care regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.